DrugPatentWatch Database Preview
Patent: 8,603,521
» See Plans and Pricing
Summary for Patent: 8,603,521
| Title: | Formulations of histone deacetylase inhibitor and uses thereof |
| Abstract: | Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. |
| Inventor(s): | Loury; David J. (San Jose, CA), Buggy; Joseph J. (Mountain View, CA), Mody; Tarak D. (Sunnyvale, CA), Verner; Erik J. (Belmont, CA), Purro; Norbert (Los Gatos, CA), Balasubramanian; Sriram (San Carlos, CA) |
| Assignee: | Pharmacyclics, Inc. (Sunnyvale, CA) |
| Application Number: | 12/761,588 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,603,521
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | Pharmacyclics, Inc. (Sunnyvale, CA) | 2029-04-17 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Pharmacyclics, Inc. (Sunnyvale, CA) | 2029-04-17 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Pharmacyclics, Inc. (Sunnyvale, CA) | 2029-04-17 | RX | Orphan | search |
| Wyeth Pharms Inc | MYLOTARG | gemtuzumab ozogamicin | VIAL;SINGLE-DOSE | 761060 | 001 | 2018-04-09 | Start Trial | Pharmacyclics, Inc. (Sunnyvale, CA) | 2029-04-17 | RX | Orphan | search |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 003 | 2006-09-27 | Start Trial | Pharmacyclics, Inc. (Sunnyvale, CA) | 2029-04-17 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,603,521
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United States of America | 10105552 | Start Trial |
| United States of America | 2011311624 | Start Trial |
| United States of America | 2014057862 | Start Trial |
| United States of America | 2015164854 | Start Trial |
| United States of America | 2017333731 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
